The Conselho Federal de Medicina (CFM) has restricted the use of hormonal implants for aesthetic purposes, muscle-mass gain, and performance enhancement in Brazil [1].
This restriction marks a significant shift in the regulation of endocrine treatments. The move comes as medical entities in Brazil remain divided over the safety and appropriateness of manipulated hormones and long-term implants.
The CFM's decision targets the growing trend of using hormonal therapy not for medical necessity, but for physical optimization. By limiting these practices, the council aims to curb the risks associated with non-therapeutic hormone manipulation—a practice that has sparked intense debate among healthcare providers.
While the primary focus of the current restriction is on performance and aesthetics, the broader conversation regarding women's health and hormonal awareness continues. Data from the Instituto Ipsos indicates that 40% [1] of Brazilian women do not know what endometriosis is, highlighting a gap in health literacy that complicates the landscape of hormonal care.
Medical entities continue to clash over whether the benefits of these implants outweigh the potential systemic risks. The CFM's intervention seeks to establish a standardized boundary for what constitutes a legitimate medical treatment versus an elective aesthetic enhancement.
“The CFM restricted the use of hormonal implants for aesthetic purposes, muscle-mass gain, and performance enhancement.”
The CFM's restrictions reflect a global tension between 'wellness' or 'optimization' medicine and traditional clinical practice. By banning the use of implants for performance and aesthetics, Brazilian regulators are prioritizing patient safety over the demand for rapid physical enhancement, signaling a crackdown on the medicalization of beauty and athletic performance.
